CHD1L is considered a cancer or prognostic biomarker, because its overexpression is usually associated with poor prognosis, such as in HCC [21], gastric cancer [22], bladder cancer [25], breast cancer [26], NSCLC [12], cholangiocarcinoma [20], and nasopharyngeal carcinoma [27]. The gene discussed is CHD1L; the disease is urinary bladder cancer.